"After humming and hawing for the last three years, it is now finally stated that the committee was not even constituted, much less a report to be submitted by the committee. We find this position unacceptable," the court said.
The court said the committee should be set up as decided in the meeting of the Drugs Technical Advisory Board (DTAB) on May 16, 2013 and the committee to submit its report to DTAB with a copy to be placed before it.
The issue relates to the Centre's decision to ban manufacture and sale of multi-dose packs of diclofenac on the ground that it was chief reason for the alarming fall in vulture population.
There were allegations that the drug was fatal to vultures which feed on carcasses of cattle that had taken diclofenac injection within 72 hours (three days) before their death.
The Centre favoured only single-dose diclofenac packs, and sought to prosecute those who manufacture and sell 30ml packs. It was, however, stayed by the high court after manufacturers of multi-dose packs filed pleas, saying there was no systematic, scientific, long-duration study documented by any reliable government agency preceding the ban order.
Members of the committee were named as Dr S D Seth, advisor, CTRI, National Institute of Medical Statistics, ICMR, New Delhi; Dr Y K Gupta, professor and head, department of pharmacology, AIIMS, New Delhi; and Dr N K Gupta, director, department of medicine, Maulana Azad Medical College, Delhi.
It was in view of this submission that the bench recently flayed the Centre on coming to know that the committee had not been constituted at all.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
